The company's 1Q20 growth amid COVID-19 was fueled by $6.8 million in sales from Parcus and Arthosurface, in addition to continuing purchase orders of legacy viscosupplements.
The company rode early 1Q momentum to grow in the low double-digits despite COVID-related procedure deferrals, and has seen signs of incremental recovery in May.
The company managed to drive single-digit growth despite the late-March impact of COVID and expects to be well-positioned to benefit from the inevitable market consolidation occurring due to the pandemic.
Precision Spine commenced U.S. launch of the Slimplicity® HP Anterior Cervical Plating (ACP) System, which accommodates diverse patient anatomies and pathologies with low profile constrained, semi-constrained or hybrid constructs....
The Naviswiss total hip replacement application is image-free and provides the surgeon with accurate information on cup alignment, leg length and offset.
Orthopedic sales for the company declined 9.5% in 1Q20 before dropping by nearly half through April. However, the company sees initial recovery signs as countries gradually restart elective procedures.
NuVasive suffered modest impact from COVID-19 in 1Q20 and expects severe reductions in 2Q. However, the company is using its strong cash position to push forward with product development.
Vericel's MACI revenue grew 22% in 1Q20 despite mid-March disruptions from COVID-19. The company believes it has passed the market low point and remains confident it will recoup most lost procedures.
3D-Side announces U.S. launch of Customize, the web-based platform to efficiently communicate, produce and design patient-specific implants.
The SPIRA-C Standalone Integrated Interbody and the FORTICO Anterior Cervical Plate are FDA 510(k)-cleared and ready for U.S. launch.